Fresenius stock: Berenberg raises target from EUR 50.00 to EUR 54.00

Published on 10/23/2026 at 16:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached EUR 5.864 billion, up 6.00 percent. Fresenius stock is EUR 45.76 on October 23, 2026, up 1.02 percent versus Xetra close.

Analyst target and reporting date

Berenberg raised its Fresenius target from EUR 50.00 to EUR 54.00 on October 23, 2026.
Second-quarter revenue reached EUR 5.864 billion, up 6.00 percent year over year.
Fresenius stock costs EUR 45.76 at Lang & Schwarz on October 23, 2026 at 4:00 p.m. CEST, 1.02 percent above the October 22, 2026 Xetra close.
Fresenius is scheduled to report third-quarter 2026 results on November 4, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius (ISIN DE000FRE5EN2) drew a fresh analyst target of EUR 54.00 on October 23, 2026, after Berenberg raised its previous EUR 50.00 target and kept a Buy rating, as t-online reported. At Lang & Schwarz on October 23, 2026 at 4:00 p.m. CEST, the stock stood at EUR 45.76, up 1.02 percent versus the Xetra close of October 22, 2026 at EUR 45.30.

Target rises as results approach

Berenberg analyst Harry Gillis expects Fresenius to deliver high-single-digit annual earnings growth over the medium term. The research view also puts the firm's 2027 forecast 2.00 percent above consensus, according to t-online. The EUR 54.00 target is 18.00 percent above the Lang & Schwarz price of EUR 45.76 on October 23, 2026 at 4:00 p.m. CEST.

Second-quarter revenue sets the base

Fresenius reported second-quarter 2026 revenue of EUR 5.864 billion, an organic increase of 6.00 percent from EUR 5.571 billion in the second quarter of 2025. Consolidated EBIT rose 10.00 percent to EUR 719.00 million from EUR 654.00 million, while core net income increased 14.00 percent to EUR 470.00 million from EUR 412.00 million, according to the company's Fresenius investor-relations page.

Stock remains below its yearly high

The Lang & Schwarz price of EUR 45.76 on October 23, 2026 at 4:00 p.m. CEST stood 13.60 percent below the 52-week high of EUR 52.96 and 30.33 percent above the 52-week low of EUR 35.11. The quoted market capitalization was EUR 25.8 billion as of October 23, 2026, while reported volume for the primary quote was 336,908 shares.

Valuation and next reporting date

Fresenius carried a price to earnings ratio of 16.59 and a trailing dividend yield of 0.02 percent on October 23, 2026. The investor-relations calendar lists November 4, 2026 for the third-quarter 2026 results, giving the revised analyst target an immediate reporting date to test.

What can the next report change?

The key comparison is between the 6.00 percent second-quarter revenue growth and the high-single-digit earnings growth expected by Berenberg. Fresenius Kabi generated EUR 2.244 billion of second-quarter revenue, up 7.00 percent year over year, while Helios reached EUR 3.526 billion, up 5.00 percent, according to the company investor-relations page. Those segment figures show where the group must maintain execution before November 4, 2026.

Price and target in view

The revised EUR 54.00 target leaves 18.00 percent between Berenberg's level and the EUR 45.76 Lang & Schwarz price on October 23, 2026 at 4:00 p.m. CEST. The next dated company milestone is the third-quarter report on November 4, 2026.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.